Mesenchymal adult stem cells, new blood vessels, heart repair, New York, USA

Angioblast Systems, Inc. is a privately held biotechnology company formed in 2001. The Company is committed to becoming a world leader in the development and commercialization of novel therapeutic products for the treatment of cardiovascular diseases (“CVD”).

Angioblast intends to achieve this goal through the advancement of its three lead and groundbreaking product candidates that have each been proven to be effective in animal models of human CVD:

1. special adult stem cells called Mesenchymal Precursor Cells
   
2. peptide-based therapeutics that induce stem cell migration, angiogenesis, and cardiovascular recovery, the lead candidate being stromal-derived factor 1
   
3. products delivered in drug-eluting stents for coronary and peripheral artery disease, consisting of RNA silencing technology, the lead candidate targeting the blood vessel and clotting regulator plasminogen activator inhibitor type I

Read more....

Business Location

Angioblast Systems, Inc.
275 Madison Ave 4th floor
New York , NY 10016
USA
Phone: (212) 880-2060
Email: info@angioblast.com